Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cogent Biosciences ( (COGT) ).
On July 7, 2025, Cogent Biosciences announced positive top-line results from Part 2 of the SUMMIT clinical trial for bezuclastinib in non-advanced systemic mastocytosis, showing significant improvements across primary and secondary endpoints. The company plans to submit a new drug application to the FDA by the end of 2025 and present detailed trial results at a medical meeting later this year, potentially strengthening its market position and offering new treatment options for patients.
The most recent analyst rating on (COGT) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.
Spark’s Take on COGT Stock
According to Spark, TipRanks’ AI Analyst, COGT is a Underperform.
Cogent Biosciences is currently facing significant financial difficulties, with no recent revenue, ongoing operating losses, and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio and absence of dividends. These factors contribute to the lowest overall stock score, highlighting substantial risks for investors.
To see Spark’s full report on COGT stock, click here.
More about Cogent Biosciences
Cogent Biosciences is a company operating in the biotechnology industry, focusing on developing precision therapies for genetically defined diseases. Their primary product focus includes treatments for systemic mastocytosis and gastrointestinal stromal tumors.
Average Trading Volume: 1,745,247
Technical Sentiment Signal: Hold
Current Market Cap: $863M
See more insights into COGT stock on TipRanks’ Stock Analysis page.